| Identification | Back Directory | [Name]
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE | [CAS]
571189-49-6 | [Synonyms]
-4-(6-aminopyridin-3-yL
5-(4-Methylpiperazin-1-yl)
5-(4-Methyl-1-piperazinyl)-2-pyridinamine
2-Amino-5-(4-methyl-1-piperazinyl)pyridine
2-Amino-5-(N-methylpiperazin-1-yl)pyridine
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE
2-PyridinaMine, 5-(4-Methyl-1-piperazinyl)-
5-(4-Methyl-piperazin-1-yl)-pyridin-2-ylamine
tert-butyl 3-allyl-3-hydroxyazetidine-17-carboxylate
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE ISO 9001：2015 REACH | [Molecular Formula]
C10H16N4 | [MDL Number]
MFCD10009563 | [MOL File]
571189-49-6.mol | [Molecular Weight]
192.27 |
| Chemical Properties | Back Directory | [Melting point ]
148 °C | [Boiling point ]
368.1±42.0 °C(Predicted) | [density ]
1.142±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Acetonitrile (Slightly), Chloroform (Slightly), Water (Slightly) | [form ]
powder to crystal | [pka]
7.41±0.42(Predicted) | [color ]
Light yellow to Brown | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C10H16N4/c1-13-4-6-14(7-5-13)9-2-3-10(11)12-8-9/h2-3,8H,4-7H2,1H3,(H2,11,12) | [InChIKey]
QDMPMBFLXOWHRY-UHFFFAOYSA-N | [SMILES]
C1(N)=NC=C(N2CCN(C)CC2)C=C1 |
| Hazard Information | Back Directory | [Chemical Properties]
Light yellow to Brown powder to crystal. | [Uses]
5-(4-Methylpiperazin-1-yl)pyridin-2-amine can be used for chemical mechanical planarization for tungsten-containing substrates. | [Synthesis]
General procedure for the synthesis of 1-methyl-4-(6-aminopyridin-3-yl)piperazine from 1-methyl-4-(6-nitropyridin-3-yl)piperazine: a mixture of 1-methyl-4-(6-nitropyridin-3-yl)piperazine (1.11 g, 5.02 mmol) and 10% Pd/C (110 mg) in methanol (15 mL) was stirred for 5 h at room temperature . Upon completion of the reaction, the catalyst was removed by filtration and the filtrate was concentrated to afford 951 mg (99% yield) of a yellow solid product, 1-methyl-4-(6-aminopyridin-3-yl)piperazine, which could be used in the subsequent reaction without further purification. The 1H NMR (CDCl3) data of the product were as follows: δ 7.78 (d, 1H, J = 3.0 Hz), 7.18 (dd, 1H, J = 3.0, 8.9 Hz), 6.48 (d, 1H, J = 8.9 Hz), 3.08 (dd, 4H, J = 4.9, 4.9 Hz), 2.61 (dd, 4H, J = 4.9, 4.9 Hz) , 2.37 (s, 3H). | [References]
[1] Journal of Medicinal Chemistry, 2017, vol. 60, # 5, p. 1892 - 1915
[2] Patent: US2005/38078, 2005, A1. Location in patent: Page/Page column 29
[3] Patent: WO2004/14904, 2004, A1. Location in patent: Page 51
[4] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 2, p. 348 - 364
[5] Patent: US2017/313683, 2017, A1. Location in patent: Paragraph 0300-0301 |
|
|